UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight

Diabetes, obesity & metabolism, 2012-06, Vol.14 (6), p.531-538

2012

Volltextzugriff (PDF)

Evaluation of β-cell mass and function in the Göttingen minipig

Diabetes, obesity & metabolism, 2007-11, Vol.9 (s2), p.170-179

2007

Volltextzugriff (PDF)

Liraglutide, a Long-Acting GLP-1 Analog, Restores Pancreatic Beta-Cell Mass and Corrects Hyperglycemia after Diabetes Onset in NOD Mice: Gastrin Potentiates Liraglutide's Effects

Diabetes (New York, N.Y.), 2005-06, Vol.54, p.A57

2005

Volltextzugriff (PDF)

Ups and downs for neuropeptides in body weight homeostasis: pharmacological potential of cocaine amphetamine regulated transcript and pre-proglucagon-derived peptides

European journal of pharmacology, 2002-04, Vol.440 (2), p.159-172

2002

Volltextzugriff (PDF)

On the Treatment of Diabetes Mellitus with Glucagon-like Peptide-1

Annals of the New York Academy of Sciences, 1998-12, Vol.865 (1), p.336-343

1998

Volltextzugriff (PDF)

Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist

Science translational medicine, 2018-11, Vol.10 (467)

2018

Volltextzugriff (PDF)

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

The Journal of clinical investigation, 2014-10, Vol.124 (10), p.4473-4488

2014

Volltextzugriff (PDF)

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

Endocrinology (Philadelphia), 2010-04, Vol.151 (4), p.1473-1486

2010

Volltextzugriff (PDF)

Characterization of the Glucagonlike Peptide-1 Receptor in Male Mouse Brain Using a Novel Antibody and In Situ Hybridization

Endocrinology (Philadelphia), 2018-02, Vol.159 (2), p.665-675

2018

Volltextzugriff (PDF)

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease

Journal of Alzheimer's disease, 2015-06, Vol.46 (4), p.877-888

2015

Volltextzugriff (PDF)

Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes

Journal of medicinal chemistry, 2004-08, Vol.47 (17), p.4128-4134

Knudsen, Lotte Bjerre

2004

Volltextzugriff (PDF)

Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease

Disease models & mechanisms, 2019-11, Vol.12 (11)

2019

Volltextzugriff (PDF)

The IGF system in patients with type 2 diabetes: associations with markers of cardiovascular target organ damage

European journal of endocrinology, 2017-05, Vol.176 (5), p.521-531

2017

Volltextzugriff (PDF)

Systemic Administration of the Long-Acting GLP-1 Derivative NN2211 Induces Lasting and Reversible Weight Loss in Both Normal and Obese Rats

Diabetes (New York, N.Y.), 2001-11, Vol.50 (11), p.2530-2539

2001

Volltextzugriff (PDF)

A genetic map of the mouse dorsal vagal complex and its role in obesity

Nature metabolism, 2021-04, Vol.3 (4), p.530-545

2021

Volltextzugriff (PDF)

A lipopolysaccharide mouse model mirrors neuroinflammatory transcriptional signatures of human Alzheimer’s disease, and the Glucagon‐Like Peptide‐1 receptor agonist semaglutide attenuates neuroinflammation in this model

Alzheimer's & dementia, 2022-12, Vol.18 (S10), p.n/a

2022

Volltextzugriff (PDF)

GLP‐1 derivative liraglutide in rats with β‐cell deficiencies: influence of metabolic state on β‐cell mass dynamics

British journal of pharmacology, 2003-09, Vol.140 (1), p.123-132

2003

Volltextzugriff (PDF)

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta -cell mass in diabetic mice

American journal of physiology: endocrinology and metabolism, 2002-10, Vol.283 (4), p.E745-E752

2002

Volltextzugriff (PDF)

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro

Biochemical and biophysical research communications, 2005-05, Vol.330 (2), p.577-584

2005

Volltextzugriff (PDF)

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

European journal of pharmacology, 1996-12, Vol.318 (2), p.429-435

1996

Volltextzugriff (PDF)

Contemporary Block Ciphers

Lecture notes in computer science, 2003, p.105-126

2003

Volltextzugriff (PDF)

The truncated metabolite GLP-2 (3–33) interacts with the GLP-2 receptor as a partial agonist

Regulatory peptides, 2002-01, Vol.103 (1), p.9-15

2002

Volltextzugriff (PDF)

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

The journal of clinical endocrinology and metabolism, 2010-03, Vol.95 (3), p.1476-1477

2010

Volltextzugriff (PDF)

Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists

Journal of medicinal chemistry, 2001-09, Vol.44 (19), p.3141-3149

2001

Volltextzugriff (PDF)

GLP-1 derivative liraglutide in rats with [beta]-cell deficiencies: influence of metabolic state on [beta]-cell mass dynamics

British journal of pharmacology, 2003-09, Vol.140 (1), p.123

2003

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(29)
Buchkapitel
(1)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight

Evaluation of β-cell mass and function in the Göttingen minipig

Liraglutide, a Long-Acting GLP-1 Analog, Restores Pancreatic Beta-Cell Mass and Corrects Hyperglycemia after Diabetes Onset in NOD Mice: Gastrin Potentiates Liraglutide's Effects

Ups and downs for neuropeptides in body weight homeostasis: pharmacological potential of cocaine amphetamine regulated transcript and pre-proglucagon-derived peptides

On the Treatment of Diabetes Mellitus with Glucagon-like Peptide-1

Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

Characterization of the Glucagonlike Peptide-1 Receptor in Male Mouse Brain Using a Novel Antibody and In Situ Hybridization

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease

Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes

Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease

The IGF system in patients with type 2 diabetes: associations with markers of cardiovascular target organ damage

Systemic Administration of the Long-Acting GLP-1 Derivative NN2211 Induces Lasting and Reversible Weight Loss in Both Normal and Obese Rats

A genetic map of the mouse dorsal vagal complex and its role in obesity

A lipopolysaccharide mouse model mirrors neuroinflammatory transcriptional signatures of human Alzheimer’s disease, and the Glucagon‐Like Peptide‐1 receptor agonist semaglutide attenuates neuroinflammation in this model

GLP‐1 derivative liraglutide in rats with β‐cell deficiencies: influence of metabolic state on β‐cell mass dynamics

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta -cell mass in diabetic mice

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

Contemporary Block Ciphers

The truncated metabolite GLP-2 (3–33) interacts with the GLP-2 receptor as a partial agonist

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists

GLP-1 derivative liraglutide in rats with [beta]-cell deficiencies: influence of metabolic state on [beta]-cell mass dynamics

Suchergebnisse filtern